Sandoz is proud to be a part of the Novartis Declaration for Patients, which Novartis introduced today at the Innovating for Patients event in Basel, Switzerland. The patient declaration is a public commitment to patients around the world of what they can expect from us as a company. It clearly states our responsibilities and commitments to patients across five key areas, from clinical trials to access to our medicines.

Click here to read more about the Novartis Declaration for Patients ( …

June 24, 2015 – Novartis has a strong history of CR activities, and transparent reporting is a central part of our commitment to corporate responsibility. We have publicly reported on our performance in this area since 2000 through our Annual Report and several online and printed materials.

The 2014 CR Performance Report aims to meet the needs and expectations of CR professional audiences by offering easy access to key data. The report also details progress against Novartis priorities, defined following a CR materiality process.

In response to feedback received …

• Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis
• Sandoz has begun shipping to US customers following recent FDA approval
• Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of support services

Holzkirchen, Germany, June 18, 2015 – Sandoz, a Novartis company, today announced the US launch of GlatopaTM, the first generic version of Teva’s Copaxone® (glatiramer acetate …

• Strong progress on innovation across divisions
  • Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and CART with immuno-oncology assets
  • Alcon is focused on eye care innovation, including strengthening its IOL pipeline over prior year and focusing on early-stage discovery in Ophthalmic Pharmaceuticals
  • Sandoz is extending its lead in differentiated generics, exemplified by first-of-a-kind FDA approvals for biosimilar Zarxio and generic Copaxone® 20mg …

Princeton, New Jersey, June 4, 2015 – Sandoz today announced the US market introduction of guanfacine hydrochloride extended release tablets, a generic version of INTUNIV®, which is currently marketed by Shire Pharmaceuticals.

Guanfacine hydrochloride extended release is a central alpha2A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. Guanfacine is not a central nervous system (CNS) stimulant. The mechanism of action of …